Drug Profile
Ropivacaine extended release - PainReform
Alternative Names: PRF 110; PRF-110-oily solutionLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator PainReform
- Class Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 13 Mar 2023 Phase-III clinical trials in Postoperative pain in USA (Parenteral) (NCT05773846)
- 18 Jul 2018 US FDA grants approval to conduct two pivotal phase III trials for extended release ropivacaine for Post-operative pain
- 02 Jun 2016 PainReform plans a phase II trial for Postoperative pain in Israel (NCT02784327)